Cyproheptadine-d3
目录号 : GC45876
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyproheptadine-d3 is intended for use as an internal standard for the quantification of cyproheptadine by GC- or LC-MS. Cyproheptadine is an antihistamine with antiserotonergic and anticholinergic activities.1 It binds to histamine H1, muscarinic, and serotonin 5-HT2 receptors (Kis = 0.38, 1.26, and 0.83 nM, respectively, in radioligand binding assays).2 Cyproheptadine reduces histamine-induced spasms in isolated guinea pig ileum (IC75 = 0.0014 μg/ml).3 It protects against intravenous histamine diphosphate-induced death with a 50% protective dose (PD50) value of 0.08 mg/kg and delays induction of aerosolized histamine diphosphate-induced coughing (ED100sec = 0.29 mg/kg) in guinea pigs. Cyproheptadine also inhibits the lysine methyltransferase SET7/9 (IC50 = 1 μM), decreasing the expression of estrogen receptor α (ERα) in MCF-7 cells.4 Formulations containing cyproheptadine have been used in the treatment of allergic reactions including rhinitis, conjunctivitis, and urticaria.
|1. Greaves, M.W. Antihistamines. Dermatol. Clin. 19(1), 53-62 (2001).|2. Kakiuchi, M., Ohashi, T., Musoh, K., et al. Studies on the novel antiallergic agent HSR-609: Its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn. J. Pharmacol. 73(4), 291-298 (1997).|3. Lish, P.M., Robbins, S.I., and Peters, E.L. Specificity of antihistamine drugs and involvement of the adrenergic system in histamine deaths in the guinea pig. J. Pharmacol. Exp. Ther. 153(3), 538-543 (1966).|4. Takemoto, Y., Ito, A., Niwa, H., et al. Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates estrogen-dependent transcription. J. Med. Chem. 59(8), 3650-3660 (2016).
| Cas No. | N/A | SDF | |
| Canonical SMILES | [2H]C([2H])([2H])N(CC/1)CCC1=C2C(C=CC=C3)=C3C=CC4=C\2C=CC=C4 | ||
| 分子式 | C21H18D3N | 分子量 | 290.4 |
| 溶解度 | Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4435 mL | 17.2176 mL | 34.4353 mL |
| 5 mM | 0.6887 mL | 3.4435 mL | 6.8871 mL |
| 10 mM | 0.3444 mL | 1.7218 mL | 3.4435 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。